US equities |
NVDA $237.29 ▲+1.43% MU $1,057.60 ▼-1.61% SPCX $163.74 ▲+3.01% MSFT $528.90 ▲+2.20% TSLA $373.35 ▲+0.74% INTC $117.23 ▼-1.76% SNDK $1,725.64 ▲+0.33% AMD $630.04 ▼-0.61%
FinancialContent

Articles published by Avalo Therapeutics

< Previous 1 2 Next >
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Appoints Ron Philip to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Purchases Optional Milestone Buyout
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Therapeutics to Participate in Upcoming Investor Conferences
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
News headline image
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
From Avalo Therapeutics
Via GlobeNewswire
Tickers AVTX
< Previous 1 2 Next >